Abstract:AIM:To investigate the impact of minimum tacrolimus (TAC) on new-onset diabetes mellitus (NODM) after liver transplantation (LT). METHODS:We retrospectively analyzed the data of 973 liver transplant recipients between March 1999 and September 2014 in West China Hospital Liver Transplantation Center. Following the exclusion of ineligible recipients, 528 recipients with a TAC-dominant regimen were included in our study. We calculated and determined the mean trough concentration of TAC (cTAC) in the year of diabetes diagnosis in NODM recipients or in the last year of the follow-up in non-NODM recipients. A cutoff of mean cTAC value for predicting NODM 6 mo after LT was identified using a receptor operating characteristic curve. TAC-related complications after LT was evaluated by χ(2) test, and the overall and allograft survival was evaluated using the Kaplan-Meier method. Risk factors for NODM after LT were examined by univariate and multivariate Cox regression. RESULTS:Of the 528 transplant recipients, 131 (24.8%) developed NODM after 6 mo after LT, and the cumulative incidence of NODM progressively increased. The mean cTAC of NODM group recipients was significantly higher than that of recipients in the non-NODM group (7.66 ± 3.41 ng/mL vs 4.47 ± 2.22 ng/mL, P < 0.05). Furthermore, NODM group recipients had lower 1-, 5-, 10-year overall survival rates (86.7%, 71.3%, and 61.1% vs 94.7%, 86.1%, and 83.7%, P < 0.05) and allograft survival rates (92.8%, 84.6%, and 75.7% vs 96.1%, 91%, and 86.1%, P < 0.05) than the others. The best cutoff of mean cTAC for predicting NODM was 5.89 ng/mL after 6 mo after LT. Multivariate analysis showed that old age at the time of LT (> 50 years), hypertension pre-LT, and high mean cTAC (≥ 5.89 ng/mL) after 6 mo after LT were independent risk factors for developing NODM. Concurrently, recipients with a low cTAC (< 5.89 ng/mL) were less likely to become obese (21.3% vs 30.2%, P < 0.05) or to develop dyslipidemia (27.5% vs 44.8%, P <0.05), chronic kidney dysfunction (14.6% vs 22.7%, P < 0.05), and moderate to severe infection (24.7% vs 33.1%, P < 0.05) after LT than recipients in the high mean cTAC group. However, the two groups showed no significant difference in the incidence of acute and chronic rejection, hypertension, cardiovascular events and new-onset malignancy. CONCLUSION:A minimal TAC regimen can decrease the risk of long-term NODM after LT. Maintaining a cTAC value below 5.89 ng/mL after LT is safe and beneficial.

Endoplasmic reticulum stress in the adipose tissue and monocyte chemoattractant protein‐1 are involved in tacrolimus‐induced diabetes mellitus

New-Onset Diabetes Mellitus in Patients with Idiopathic Membranous Nephropathy Undergoing Tacrolimus and Low-Dose Corticosteroid Therapy.

Tacrolimus Decreases Insulin Sensitivity Without Reducing Fasting Insulin Concentration: a 2-Year Follow-Up Study in Kidney Transplant Recipients

The Tacrolimus-Induced Glucose Homeostasis Imbalance in Terms of the Liver: from Bench to Bedside

Tacrolimus Induces Insulin Resistance and Increases the Glucose Absorption in the Jejunum: A Potential Mechanism of the Diabetogenic Effects

Increased Macrophage Activation Inhibited by Tacrolimus in the Kidney of Diabetic Rats

Tacrolimus Causes Hypertension by Increasing Vascular Contractility via RhoA (Ras Homolog Family Member A)/ROCK (Rho-Associated Protein Kinase) Pathway in Mice

Gut microbiota and metabolomic profile changes play critical roles in tacrolimus-induced diabetes in rats

Tacrolimus-Induced BMP/SMAD Signaling Associates With Metabolic Stress–Activated FOXO1 to Trigger β-Cell Failure

Antibiotics-mediated Intestinal Microbiome Perturbation Aggravates Tacrolimus-Induced Glucose Disorders in Mice

Regenerating islet‐derived protein 3 gamma (Reg3g) ameliorates tacrolimus‐induced pancreatic β‐cell dysfunction in mice by restoring mitochondrial function

Induction of diabetes by Tacrolimus in a phenotypic model of obesity and metabolic syndrome

Regenerating islet-derived protein 3 gamma (Reg3g) ameliorates tacrolimus-induced pancreatic -cell dysfunction in mice by restoring mitochondrial function

Minimizing Tacrolimus Decreases the Risk of New-Onset Diabetes Mellitus after Liver Transplantation

Advances in the study of post-transplantation diabetes mellitus resulting from tacrolimus via calcineurin/NFAT signaling

Tacrolimus Ameliorates Tubulointerstitial Inflammation in Diabetic Nephropathy Via Inhibiting the NFATc1/TRPC6 Pathway

The Effect of Tacrolimus on Carbohydrate Metabolism and Controlling

Effects of conversion from tacrolimus to cyclosporine A therapy on new-onset diabetes mellitus after kidney transplantation

Effect of tacrolimus on macrophage accumulation, proliferation and activation in the kidney of early diabetic rats

Tacrolimus Increases the Expression Level of the Chemokine Receptor CXCR2 to Promote Renal Fibrosis Progression.

Tacrolimus Combined with Corticosteroids in Treatment of Nephrotic Idiopathic Membranous Nephropathy: A Multicenter Randomized Controlled Trial